Regeneron

R2810-ONC-1676

NCT03257267

JCP030

An Open-Label, Randomized, Phase 3 Clinical Trial Of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Cemiplimab (REGN2810)

Human programmed death receptor -1 (PD-1) monoclonal antibody (i.v.)

Treatment Arms

o Experimental: Experimental Therapy

o Active Comparator: Control Therapy